SG11201508433TA - Therapeutic delivery vesicles - Google Patents

Therapeutic delivery vesicles

Info

Publication number
SG11201508433TA
SG11201508433TA SG11201508433TA SG11201508433TA SG11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA
Authority
SG
Singapore
Prior art keywords
therapeutic delivery
delivery vesicles
vesicles
therapeutic
delivery
Prior art date
Application number
SG11201508433TA
Inventor
Andaloussi Samir El
Oscar WIKLANDER
Joel NORDIN
Edvard Smith
Karl-Henrik Grinnemo
Oscar Simonson
Original Assignee
Andaloussi Samir El
Oscar WIKLANDER
Joel NORDIN
Edvard Smith
Karl-Henrik Grinnemo
Oscar Simonson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20296661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201508433T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andaloussi Samir El, Oscar WIKLANDER, Joel NORDIN, Edvard Smith, Karl-Henrik Grinnemo, Oscar Simonson filed Critical Andaloussi Samir El
Publication of SG11201508433TA publication Critical patent/SG11201508433TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C1/00—Rotary-piston machines or engines
    • F01C1/30—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members
    • F01C1/34—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members
    • F01C1/344—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member
    • F01C1/3441—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation
    • F01C1/3442—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation the surfaces of the inner and outer member, forming the working space, being surfaces of revolution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C21/00—Component parts, details or accessories not provided for in groups F01C1/00 - F01C20/00
    • F01C21/10—Outer members for co-operation with rotary pistons; Casings
    • F01C21/102—Adjustment of the interstices between moving and fixed parts of the machine by means other than fluid pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG11201508433TA 2013-04-12 2014-04-10 Therapeutic delivery vesicles SG11201508433TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1300271 2013-04-12
PCT/SE2014/000047 WO2014168548A2 (en) 2013-04-12 2014-04-10 Therapeutic delivery vesicles

Publications (1)

Publication Number Publication Date
SG11201508433TA true SG11201508433TA (en) 2015-11-27

Family

ID=20296661

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508433TA SG11201508433TA (en) 2013-04-12 2014-04-10 Therapeutic delivery vesicles

Country Status (11)

Country Link
US (3) US11274139B2 (en)
EP (2) EP3335721A1 (en)
JP (3) JP6542197B2 (en)
AU (1) AU2014251388B2 (en)
CA (1) CA2910802A1 (en)
DK (1) DK2983721T4 (en)
ES (1) ES2662326T5 (en)
HK (1) HK1257101A1 (en)
PT (1) PT2983721T (en)
SG (1) SG11201508433TA (en)
WO (1) WO2014168548A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
CA2910802A1 (en) 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
CA3205855A1 (en) 2013-04-16 2014-10-23 Orbsen Therapeutics Limited Medical use of syndecan-2
AU2015264519B2 (en) 2014-05-18 2021-01-28 Children's Medical Center Corporation Methods and compositions relating to exosomes
GB201418562D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
JP6920207B2 (en) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド Cindecan-2 modulator and its use
KR101912315B1 (en) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Process for preparing exosome loading Bcl-2-associated X protein, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
WO2018062973A1 (en) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions containing protein loaded exosome and methods for preparing and delivering the same
KR101900465B1 (en) * 2016-10-13 2018-09-19 주식회사 셀렉스라이프사이언스 Technology to deliver the genome editing tool by using the CRISPR-CAS family
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
KR101912310B1 (en) * 2016-10-04 2018-10-26 주식회사 셀렉스라이프사이언스 Process for preparing exosome loading Peroxiredoxin I or II protein, and pharmaceutical composition for use in antioxidant containing the same as an active ingredient
KR101877010B1 (en) * 2016-09-30 2018-08-09 한국과학기술원 Process for preparing exosome loading super-repressor-IκB protein, and pharmaceutical composition for use in preventing or treating inflammatory diseases containing the same as an active ingredient
KR20160130937A (en) * 2015-05-04 2016-11-15 한국과학기술원 Process for preparing exosome loading target protein and method for loading target protein to cytosol by using exosome prepared thereby
KR101912313B1 (en) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Process for preparing exosome loading cre recombinase, and pharmaceutical composition for use in generating conditional knock-out alleles containing the same as an active ingredient
WO2016178532A1 (en) * 2015-05-04 2016-11-10 한국과학기술원 Production method for exosome comprising target protein, and method for transferring target protein into cytoplasm by using exosome produced by means of the production method
BR112017026467A2 (en) * 2015-06-10 2018-09-11 Univ Texas use of exosomes to treat disease
CN108368487B (en) * 2015-10-01 2022-02-01 渥太华大学 Exosome packaging of nucleic acids
WO2017054086A1 (en) * 2015-10-01 2017-04-06 Exerkine Corporation Treatment of genetic myopathies using bioengineered exosomes
SG11201804117XA (en) 2015-11-18 2018-06-28 Univ Georgia Neural cell extracellular vessicles
EP3922253A1 (en) * 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552460A (en) * 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
GB2552301A (en) * 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
KR102120921B1 (en) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Process for preparing exosome loading β-glucocerebrosidase, and pharmaceutical composition for use in preventing and treating Gaucher Disease containing the same as an active ingredient
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
AU2018238010A1 (en) * 2017-03-21 2019-10-31 Exoprother Medical Ltd. Native cell derived vesicles containing tumor suppressor proteins for therapy
JP7395355B2 (en) 2017-05-08 2023-12-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Compositions and uses thereof for promoting membrane fusion
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
AU2018300272A1 (en) 2017-07-14 2020-02-06 Orbsen Therapeutics Limited CD39 stromal stem cells methods of isolation and use
KR20200037353A (en) 2017-08-07 2020-04-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 Platform for creating safe cell therapy products
WO2019035880A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation Purifield mesenchymal stem cell exosomes and uses thereof
WO2019035057A2 (en) * 2017-08-17 2019-02-21 Cellex Life Sciences, Incorporated Exosomes for target specific delivery and methods for preparing and delivering the same
CA3073162C (en) * 2017-08-17 2023-07-04 Ilias Biologics Inc. Exosomes for target specific delivery and methods for preparing and delivering the same
EP3673063A1 (en) 2017-08-21 2020-07-01 Resurgo Genetics Limited Methods of changing transcriptional output
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
TR201720642A2 (en) * 2017-12-18 2019-07-22 Univ Yeditepe GUIDED CAFE LOADED MICROVESICULAR CANCER DRUG AND METHOD OF ITS IMPROVEMENT
WO2019122279A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
MX2020005754A (en) 2017-12-22 2020-08-20 Roche Innovation Ct Copenhagen As Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage.
KR20200104302A (en) 2017-12-22 2020-09-03 로슈 이노베이션 센터 코펜하겐 에이/에스 New thiophosphoramidite
GB201802163D0 (en) * 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
KR20200144093A (en) 2018-02-17 2020-12-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Compositions and methods for membrane protein delivery
WO2019169216A1 (en) * 2018-03-01 2019-09-06 Rhode Island Hospital Exosome targeting of cd4+ expressing cells
GB201809622D0 (en) 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification
AU2019323122A1 (en) 2018-08-14 2021-02-25 Evercyte Gmbh Target-specific extracellular vesicles
WO2020043750A1 (en) 2018-08-28 2020-03-05 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
SG11202105085QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Compositions and methods for compartment-specific cargo delivery
EP3654215B1 (en) 2018-11-15 2021-06-30 Sternum Ltd. Applying control flow integrity verification in intermediate code files
WO2020154746A1 (en) * 2019-01-25 2020-07-30 Mantra Bio, Inc. Skeletal muscle targeting moieties and uses thereof
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
AU2020298314A1 (en) * 2019-06-21 2022-02-03 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
KR102553337B1 (en) * 2019-08-20 2023-07-10 (주)메디톡스 Extracellular vesicle isolated from recombinant cells comprising polynucleotide encoding IL-1 blockade as target protein and use thereof
CN115443124A (en) 2020-02-05 2022-12-06 戴尔戴莫生物医疗有限公司 Artificial synapse
WO2021163416A1 (en) * 2020-02-12 2021-08-19 President And Fellows Of Harvard College Methods of measuring and purifying extracellular vesicles
CA3175322A1 (en) * 2020-03-17 2021-09-23 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
CN111529504B (en) * 2020-03-25 2023-01-10 西安组织工程与再生医学研究所 Functional chimeric apoptotic body and preparation method and application thereof
CN111529505B (en) * 2020-03-25 2023-04-11 西安组织工程与再生医学研究所 Functional chimeric apoptotic body and preparation method and application thereof
CA3173845A1 (en) * 2020-03-31 2021-10-07 Chulhee Choi Use of exosome-based delivery of nf-kb inhibitors
KR102636371B1 (en) * 2020-04-10 2024-02-19 한국과학기술연구원 Novel recombinant exosome and use thereof
KR102341138B1 (en) 2020-05-31 2021-12-21 주식회사 엑소코바이오 Exosomes comprising exosomal membrane protein variant and manufacturing method thereof
CN111588704B (en) * 2020-07-01 2023-04-11 西安组织工程与再生医学研究所 Targeted responsive release system and preparation method and application thereof
CN111803617A (en) * 2020-07-16 2020-10-23 卡杜兰(广州)生命基因工程科技有限公司 Microcapsule-loaded stem cell system and preparation method thereof
KR20220101559A (en) 2021-01-11 2022-07-19 주식회사 엑소코바이오 Exosome comprising overexpressed Fc receptor or its part and manufacturing method thereof
KR20220106696A (en) 2021-01-21 2022-07-29 주식회사 엑소코바이오 Recombinant exosome comprising Fc receptor or its part which can be fused to target protein or peptide and its use
CN113166724A (en) * 2021-03-30 2021-07-23 深圳市创生芯科生物科技有限公司 Method for preparing exosomes for any clinical use from ipscs and derivatives thereof
JP2024513087A (en) 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ Compositions and methods for site-specific modification
KR20240004598A (en) * 2021-04-23 2024-01-11 아불로션 아베 Extracellular vesicles from mesenchymal stromal cells for disease treatment
CN113616811B (en) * 2021-08-18 2023-12-05 南京中医药大学 Fusion type multifunctional nano vesicle modified by apolipoprotein and preparation method and application thereof
WO2023102550A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
CN114848608B (en) * 2022-05-17 2024-01-30 东南大学 Protein or polypeptide delivery carrier and preparation method and application thereof
EP4282951A1 (en) * 2022-05-25 2023-11-29 École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Nantes-Atlantique (ONIRIS) Method for obtaining extracellular vesicles from beta cells
US20240018480A1 (en) * 2022-07-15 2024-01-18 ExoTop Theragnostics Inc. Enhancement of extracellular vesicle production by lysosome inhibitor
CN117802045A (en) * 2022-09-30 2024-04-02 北京恩康医药有限公司 Construction and application of engineering extracellular vesicles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
JP3693209B2 (en) * 1996-04-11 2005-09-07 三菱化学株式会社 Method for producing closed vesicles
AU5541799A (en) * 1998-03-31 1999-11-29 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
FR2788780B1 (en) * 1999-01-27 2001-03-30 Ap Cells Inc PROCESS FOR THE PREPARATION OF MEMBRANE VESICLES
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US7704964B2 (en) 2001-08-17 2010-04-27 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
AU2002334161B2 (en) * 2001-10-13 2007-03-29 Asterion Limited Chimeric glycosylphosphatidylinositol containing peptides
EP1883427A4 (en) * 2005-01-20 2010-04-21 Univ Rochester Compositions and methods for studying and treating inflammatory diseases and disorders
US8455188B2 (en) 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2010056337A2 (en) † 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010108048A2 (en) * 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
JP5713325B2 (en) 2009-04-17 2015-05-07 アイシス イノヴェイション リミテッド Composition for delivery of genetic material
US20130059793A1 (en) * 2010-02-08 2013-03-07 Board Of Regents, The University Of Texas System Egf receptor mimicking peptides
SG190450A1 (en) * 2010-12-20 2013-06-28 Agency Science Tech & Res Method of purifying exosomes
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20130028895A1 (en) 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
CA2910802A1 (en) 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles

Also Published As

Publication number Publication date
EP3335721A1 (en) 2018-06-20
DK2983721T3 (en) 2018-03-19
JP2022058390A (en) 2022-04-12
HK1257101A1 (en) 2019-10-11
EP2983721B2 (en) 2021-01-20
CA2910802A1 (en) 2014-10-16
DK2983721T4 (en) 2021-02-01
US11274139B2 (en) 2022-03-15
WO2014168548A3 (en) 2014-12-04
WO2014168548A2 (en) 2014-10-16
ES2662326T3 (en) 2018-04-06
US20200207833A1 (en) 2020-07-02
JP2019167378A (en) 2019-10-03
WO2014168548A8 (en) 2015-01-29
EP2983721A2 (en) 2016-02-17
US20160137716A1 (en) 2016-05-19
AU2014251388A1 (en) 2015-11-12
ES2662326T5 (en) 2021-08-04
PT2983721T (en) 2018-03-13
EP2983721B1 (en) 2018-02-21
US11649272B2 (en) 2023-05-16
JP2016516768A (en) 2016-06-09
AU2014251388B2 (en) 2017-03-30
JP6999601B2 (en) 2022-02-04
JP6542197B2 (en) 2019-07-10
US20230111666A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
HK1257101A1 (en) Therapeutic delivery vesicles
HK1221672A1 (en) Nasal administration
HK1211517A1 (en) Drug delivery device
HK1211520A1 (en) Drug delivery device
IL245544A0 (en) Drug delivery system
SG11201508647UA (en) Drug delivery device
EP2961469A4 (en) Drug delivery device
HK1211519A1 (en) Drug delivery device
GB201313782D0 (en) Drug delivery device
IL244286B (en) Medicament delivery device
SG11201600371XA (en) Drug delivery device
GB201308917D0 (en) Delivery
HK1219451A1 (en) Drug delivery device
HK1219682A1 (en) Drug delivery device
GB201308440D0 (en) Therapeutic
HK1219685A1 (en) Drug delivery device
HK1219450A1 (en) Drug delivery device
HK1221412A1 (en) Vesicles
HK1219681A1 (en) Drug delivery device
GB2519596B (en) Medicament Delivery device
GB201318668D0 (en) Sonosensitive therapeutic
HK1221921A1 (en) Drug delivery device
HK1219680A1 (en) Drug delivery device
HK1223052A1 (en) Drug delivery device
IL245007A0 (en) Drug delivery device